U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H26O4
Molecular Weight 366.4501
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of L-152804

SMILES

CC1(C)CC(=O)C(C2C3=C(OC4=C2C(=O)CC(C)(C)C4)C=CC=C3)C(=O)C1

InChI

InChIKey=XQDXIHYKAGHZRX-UHFFFAOYSA-N
InChI=1S/C23H26O4/c1-22(2)9-14(24)20(15(25)10-22)19-13-7-5-6-8-17(13)27-18-12-23(3,4)11-16(26)21(18)19/h5-8,19-20H,9-12H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16377459 | https://www.ncbi.nlm.nih.gov/pubmed/22367168

L-152804 is a nonpeptide, potent, selective and orally available antagonist of a neuropeptide-Y Y5 receptor (NPY Y5). L-152,804 may attenuate drug-induced behavioral effects in vivo. L-152,804 prominently decreased nose-poking for the peak dose of cocaine and shifted the dose-response curve for cocaine downward in self-administration animal model of cocaine addiction-related behavior. Cocaine failed to increase c-fos expression in the nucleus accumbens and striatum of L-152,804-treated mice, indicating that the Y5 antagonist could act by influencing neural activity in these regions. Accordingly, the cocaine-induced increase in accumbal extracellular dopamine was attenuated by L- 152,804 and in Y5-KO mice, suggesting that Y5 antagonism influences cocaine-induced behavior by regulating dopamine. L-152,804 significantly reduced both the dosage of self-administered ethanol and the total number of ethanol-reinforced responses in a rodent genetic animal model of alcoholism. The most likely mechanism by which L-152,804 might have decreased g/kg ethanol intake in both behavioral models is by attenuation of its reinforcing properties. This was evidenced by reduced ethanol-reinforced responding in the absence of changes in response onset, which suggests that the NPY Y5 antagonist did not alter neurobiological processes that control the onset of ethanol responding but inhibited responding once it was initiated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
26.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.
2008 Aug 14
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/22367168
Male alcohol-preferrin rats were treatment i.p. with L-152,804 at a doses 0, 3 or 10 mg/kg as a single dose Male NMRI mice were treatment p.o. with L-152,804 at a doses 3, 10 and 30 mg/kg as a single dose
Route of Administration: Other
COS-7 cells were used in Dopamine uptake experiment. COS-7 cells were transfected with pcDNA3 SynDAT using Lipo2000 reagent (Invitrogen) in a Lipo2000: DNA ratio of 3:1. The cells were subsequently plated in poly-L-ornithine coated 24-well dishes. The number of DAT-expressing cells per well was corrected to achieve an uptake level of no more than 10% of total added [3H] dopamine (normally 10^5 cells/well). The uptake assays were carried out 2 days after transfection. Prior to the experiment, the cells were washed once in 500 μl of uptake buffer (25 mM HEPES, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM L-ascorbic acid, 5 mM D-glucose and 1 μM of the catechol-O-methyltransferase inhibitor Ro 41-0960 (Sigma), pH 7.4) at room temperature. L-152804 (1nM-1mM) was added to the cells in the indicated concentrations, and uptake was initiated by addition of 4–7 nM [3 H]dopamine in a final volume of 500 μl. After 5-min incubation at room temperature, the cells were washed twice with 500 μl of ice cold uptake buffer, lysed in 250 μl 1%SDS and left for 30 min at 37°C. All samples were transferred to 24-well counting plates (PerkinElmer); 500 μl of Opti-phase Hi Safe 3 scintillation fluid (PerkinElmer) was added, followed by counting of the plates in a Wallac Tri-Lux β-scintillation counter (PerkinElmer). Non-specific uptake was determined in the presence of 1 μM nomifensine (Sigma).
Name Type Language
L-152804
Common Name English
1,3-CYCLOHEXANEDIONE, 5,5-DIMETHYL-2-(2,3,4,9-TETRAHYDRO-3,3-DIMETHYL-1-OXO-1H-XANTHEN-9-YL)-
Systematic Name English
1,3-CYCLOHEXANEDIONE, 5,5-DIMETHYL-2-(1,2,3,4-TETRAHYDRO-3,3-DIMETHYL-1-OXOXANTHEN-9-YL)-
Systematic Name English
9-(4,4-DIMETHYL-2,6-DIOXOCYCLOHEXYL)-1,2,3,4-TETRAHYDRO-3,3-DIMETHYL-1-XANTHENONE
Systematic Name English
Code System Code Type Description
FDA UNII
AP9351PWPR
Created by admin on Sat Dec 16 09:23:18 GMT 2023 , Edited by admin on Sat Dec 16 09:23:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID30983630
Created by admin on Sat Dec 16 09:23:18 GMT 2023 , Edited by admin on Sat Dec 16 09:23:18 GMT 2023
PRIMARY
CAS
6508-43-6
Created by admin on Sat Dec 16 09:23:18 GMT 2023 , Edited by admin on Sat Dec 16 09:23:18 GMT 2023
PRIMARY
PUBCHEM
3765615
Created by admin on Sat Dec 16 09:23:18 GMT 2023 , Edited by admin on Sat Dec 16 09:23:18 GMT 2023
PRIMARY